High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death

Kidney International

Volumn 74, Issue 5, 2008, Pages 655-663

  Blayney, Margaret J ^a   Pisoni, Ronald L ^a   Bragg Gresham, Jennifer L ^a   Bommer, Juergen ^b   Piera, Luis ^c   Saito, Akira ^d   Akiba, Takashi ^e   Keen, Marcia L ^f   Young, Eric W ^a,g   Port, Friedrich K ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d TOKAI UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f AMGEN INC   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alkaline phosphatase; DOPPS; Hemodialysis; Mineral metabolism; Parathyroidectomy

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CASE MIX; COMORBIDITY; DEATH; FEMALE; FRACTURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFECTION; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CALCIUM; CARDIOVASCULAR DISEASES; FEMALE; HOSPITALIZATION; HUMANS; INFECTION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 49749139700     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.248     Document Type: Article

References (43)

1. Petrauskiene V, Bumblyte IA, Kuminskis V et al. Early risk factors for secondary hyperparathyroidism in hemodialysis patients. Medicina (Kaunas) 2005; 41(Suppl 1): S44-S49.
2. Jorna FH, Tobe TJ, Huisman RM et al. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplantation 2004; 19: 1168-1173.
3. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419.
4. Jarava C, Armas JR, Palma A. Study of renal osteodystrophy by bone biopsy. Age as an independent factor. Diagnostic value of bone remodeling markers. Nefrologia 2000; 20: 362-372.
5. Salgueira M, Milan JA, Moreno Alba R et al. Cardiac failure and diastolic disfunction in hemodialysis patients: associated factors. Nefrologia 2005; 25: 668-677.
6. Nasri H, Baradaran A, Naderi AS. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Acta Med Austriaca 2004; 31: 67-72.
7. Sanchez Navarro MR, Fernandez-Conde ME, Blanco Martin S et al. Alkaline phosphatase isoenzymes in the serum of patients with renal insufficiency. An Med Interna 2002; 19: 449-452.
8. Kubota M, Haruta T. Neutrophil alkaline phosphatase activity in respiratory viral infection. J Infect Chemother 2006; 12: 387-390.
9. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. E-pub 5 Jul 2006.
10. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2004; 67: 1179-1187.
11. Nakai S, Wada A, Kitaoka T et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Therac Apher Dial 2006; 10: 476-497.
12. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
13. Stein J, Hutton J, Kohler P et al. Internal Medicine, 4th edn, St Louis: Mosby, 2004.
14. Gonnelli S, Cepollaro C, Montagnani A et al. Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone disease. Eur J Clin Invest 1996; 26: 391-396.
15. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77: 1046-1053.
16. Moe S, Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
17. Basile C, Lomonte C, Vernaglione L et al. A high body mass index and female gender are associated with an increased risk of nodular hyperplasia of parathyroid glands in chronic uraemia. Nephrol Dial Transplant 2006; 21: 968-974.
18. Gerakis A, Hutchinson AJ, Apostolou T et al. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438.
19. Albalate M, de la Piedra C, Fernandez C et al. Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1626-1632.
20. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156.
21. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease http://www.kidney.org/professionals/kdoqi/ guidelines_bone/index.htm (accessed 7/13/2007).
22. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
23. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. Circ Res 2006; 99: e2.
24. 3. J Lab Clin Med 1979; 93: 899-909.
25. Lomonte C, Vernaglione L, Cazzato F et al. Post-parathyroidectomy serum phosphate kinetics is peculiar to female hemodialysis patients with high body mass index. J Nephrol 2006; 19: 70-76.
26. Morrone LF, Tampoia M, Pansini N et al. Kinetics of the circulating levels of bone alkaline phosphatase in a case of hungry bone disease following total parathyroidectomy. Ann Ital Med Int 2004; 19: 189-192.
27. Liu YL, Lin HH, Yu CC et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail 2006; 28: 701-707.
28. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914.
29. Chertow GM, Burke SK, Paolo Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
30. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
31. Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in dialysis patient with secondary hyperparathyroidism treated with cinacalcet - proposal for an improved monitoring. Clin Lab 2006; 52: 583-587.
32. Lazar ES, Stankus N. Cinacalcet-induced hungry bone syndrome. Semin Dial 2007; 20: 83-85.
33. Ali AT, Paiker JE, Crowther NJ. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin. Am J Clin Pathol 2006; 126: 437-442.
34. Kerner A, Avizohar O, Sella R et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005; 25: 193-197.
35. Skillen AW, Pierides AM. Serum alkaline phosphatase isoenzyme patterns in patients with chronic renal failure. Clin Chim Acta 1977; 80: 339-346.
36. Alpers DH, DeSchryver-Kecskemeti K, Goodwin CL et al. Intestinal alkaline phosphatase in patients with chronic renal failure. Gastroenterology 1988; 94: 62-67.
37. Tibi L, Chhabra SC, Sweeting VM et al. Multiple forms of alkaline phosphatase in plasma of hemodialysis patients. Clin Chem 1991; 37: 815-820.
38. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2002; 57(Suppl. 74): S-74-S-81.
39. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study: design, data elements, and methodology. Am J Kidney Disease 2004; 44(Suppl 2): S7-S15.
40. Rajagopalan S, Dellegrottaglie S, Furniss AL et al. Peripheral arterial disease in patients end-stage renal disease: obervations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation 2006; 114: 1914-1922.
41. SAS Institute Inc. SAS/STAT User's Guide. Version 8. Vol 2: 1452. SAS Institute: Cary, NC, USA, 2000.
42. Klein JP, Moeschberger ML. Survival Analysis Techniques for Censored and Truncated Data. Speinger: New York, 1997.
43. von Elm E, Altman DG, Egger M et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573-577.